Valiant Organics has disclosed details about their deal with DVLLP, concerning 1.86 million shares of Valiant Labs. The transaction includes a Rs. 6.34 crore capital adjustment payment, but they're still waiting for necessary approvals to complete the 60-day period.

Valiant Organics' Q4 earnings showed a significant 30% increase in EBITDA, reaching ₹265M compared to last year. The company also reported an improvement in margins, rising to 12.2%.

Valiant Organics has decided to investigate potential restructuring moves such as mergers, spin-offs, or organizational changes, with the aim of streamlining their structure and uncovering hidden value.

Valiant Organics reported a significant 331% surge in Q4 net profit for FY26, reaching ₹15.7 crore. However, the company's profitability has been on a downward trend, and its performance lags behind expectations.

Valiant Organics has announced a Board meeting on May 16, 2026, implying they will be discussing and possibly revealing their recent financial results soon. Stay tuned for updates.